More stories
Risk & Insurance
In the News
A Breakthrough in Pain Management: Inside the Promise of Journavx
Enlyte’s Nikki Wilson offers a fresh take on a promising alternative to opioids, a first-of-its-kind FDA-approved non-addictive medication for pain.
Register Now
Virtual Event
Resilience Redefines Results
On-Demand
Join our upcoming webinar to discover how resilience can be a game-changer in driving better outcomes for injured employees. From accelerating recovery to improving return-to-work success, resilience plays a critical role in both mental and physical well-being.
Workers' Comp
Case Study
Practical Application of Behavioral Coaching Techniques
This case study showcases the power of behavioral coaching techniques in transforming an injured employee’s recovery. Through empathy, active listening, and strategic intervention, Enlyte’s Telephonic Case Manager helped break barriers to healing—leading to improved outcomes, renewed engagement and meaningful cost savings.
Workers' Comp
White Paper
From Setback to Comeback: Effective Solutions for Delayed Recovery
Learn how to effectively ignite workers' compensation recovery by addressing some of the biggest return-to-work obstacles, including mental health comorbidities, social factors, and delayed intervention. See how data-driven strategies lead to successful claims management and faster employee recovery.
Workers' Comp
Podcast
Pulsing Recovery: Bone Growth Stimulation's Impact on Comp
Discover how bone growth stimulators are accelerating recovery in workers’ comp. Nicole Usher joins the Enlyte Envision podcast to discuss how BGS devices support healing in complex fractures and spinal surgeries.
Workers' Comp
Article
Ask The Pharmacist: FDA Approval of Non-Opioid Medication for Acute Pain
The U.S. Food and Drug Administration (FDA) recently approved Journavx (suzetrigine), a novel non-opioid medication developed by Vertex Pharmaceuticals for the treatment of moderate to severe acute pain in adults. This approval, announced on January 30, 2025, marks a significant milestone in pain management, introducing the first new class of oral medication for acute pain in over two decades.